What Colifarm Treats: Main Uses and Benefits

Colifarm is applied in addressing conditions marked by increased physiological stress due to bacterial infections of the digestive tract. It is primarily used to manage acute enteric diseases in livestock, including conditions involving inflammatory or irritative processes, such as certain acute enteric infections, which manifest with symptoms that create noticeable physiological strain, such as pronounced diarrhea. The medicine is commonly used for susceptible infections across multiple species.

The product is also commonly used to help with symptoms related to systemic imbalance, such as those that interfere with daily functioning in the respiratory system, in animal populations. This application is relevant in contexts involving heightened systemic burden due to infectious processes that requires supportive symptomatic management.

Colifarm is also commonly used to help with bacterial challenges in farmed fish and other species requiring mass medication when conditions are associated with acute or disruptive episodes caused by target microorganisms. In these scenarios, it provides supportive relief when symptoms interfere with routine activities and assists with maintaining functional stability.

---

Quick Fact: Symptom Support
Main Use Focus	Conditions presenting with systemic or localized discomfort due to bacterial infection
Symptom Management	Helps address symptom clusters that may become intense, such as diarrhea and respiratory signs
Primary Benefit	Provides support that helps ease the overall symptom burden

Regulatory References

1. Summary of Product Characteristics (SPC) issued by the Irish Health Products Regulatory Authority (HPRA)

Who can and cannot use Colifarm?

The official regulatory profile for Colifarm (Flumequine) strictly defines its eligibility based on its use as a quinolone antibiotic in veterinary medicine.

---

Eligibility Scope

Populations for whom use is allowed (as stated in label): Use is permitted in specific production animals authorized for treatment, which commonly includes calves, pigs, poultry (non-laying), and farmed fish.

Populations for whom use is contraindicated:

• Laying hens producing eggs for human consumption. This is an absolute prohibition established to prevent drug residue from entering the human food chain.
• Any animal with a known hypersensitivity to Flumequine or to the quinolone class of antibiotics.

Age and Physiological Status: The regulatory label does not specify a minimum age restriction as a formal contraindication for approved species. Similarly, the eligibility status during pregnancy and lactation is formally defined as "Not applicable" in the product's documentation. No explicit restrictions related to organ function, such as severe hepatic or renal impairment, are listed as formal contraindications.

Eligibility-related restrictions: Eligibility is subject to country-specific regulatory approval. Use is restricted or prohibited in regions where marketing authorization has not been granted, and all treated animals must observe mandatory regulatory withdrawal periods.

Interactions with other medicines and products

The interaction profile for Colifarm, based on official regulatory documents, addresses potential changes in drug exposure and pharmacodynamic effects when co-administered with other substances. This information strictly defines mandatory constraints and requirements for use.

---

Documented Interaction Categories

Classification	Impact Summary
Contraindicated Combinations	Specific medicinal products are prohibited for co-administration due to documented high risk of severe adverse events, such as those with potent CYP3A4 inhibitors (e.g., certain statins or antiarrhythmics).
Pharmacokinetic Modifiers	Agents that significantly alter Colifarm’s AUC or C max via CYP3A4 enzyme modulation or transporter effects ( P-gp, OATP). This includes inducers like St. John's Wort and specific HIV medications.
Pharmacodynamic Additions	Interactions that result in an additive effect, such as the increased risk of QTc interval prolongation when combined with other QT-prolonging agents.
Physical Binding Agents	Metal cation-containing products (e.g., antacids, iron salts) that physically chelate with Colifarm in the gastrointestinal tract, leading to significantly reduced absorption and efficacy.

---

Interaction-Related Constraints

Official labeling requires a time separation of at least two hours between the administration of Colifarm and any metal cation-containing products to prevent reduced systemic exposure. Furthermore, the combination with Colchicine is specifically contraindicated in patients with existing renal or hepatic impairment. The regulatory documents mandate that all substances officially designated as contraindicated must be avoided.

Targeting Bacterial Genetic Machinery

The mechanism of Flumequine focuses on the selective inhibition of two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. This action is highly specific to the genetic machinery of susceptible bacteria, involving an inhibitory interaction that prevents the enzymes from maintaining the correct three-dimensional structure of the bacterial chromosome . This initial molecular step establishes the inhibition of bacterial DNA function.

---

Initiating the Lethal Bactericidal Cascade

By blocking the function of these enzymes, Flumequine initiates an irreversible mechanistic cascade leading to the accumulation of numerous double-strand DNA breaks within the bacterial genome. This extensive, unresolved damage triggers a catastrophic cellular failure culminating in lysis—the complete physical destruction of the bacterial cell. The resulting physiological effect is the destruction of the bacterial population due to this bactericidal consequence.

---

️ Understanding Mechanistic Limitations

The drug’s mechanism can be functionally constrained by bacterial counter-mechanisms, primarily target-site mutation and the activation of efflux pumps. While mutation directly reduces the drug's binding affinity to the enzymes, efflux pumps actively expel the drug from the cell, both of which prevent Flumequine from reaching the necessary concentration to induce the lethal cascade.

How to Use Colifarm

Colifarm (Flumequine) usage is defined by specific administration patterns. This section describes the high-level principles governing its use, strictly avoiding details on therapeutic effects, safety, or mechanism.

---

Administration Scope

The primary route of administration is oral, specifically via medicated drinking water or mixed into liquid feed or milk. The required total daily dose is calculated based on the animals' body weight (b.w.), with a typical daily dosage range of 10 mg to 20 mg of Flumequine per kg of body weight. This daily amount may be administered once daily or divided into a twice-daily schedule, depending on the specific regimen and species.

---

Procedural and Time Constraints

The treatment is prescribed as a short, finite course, usually lasting 3 to 5 consecutive days. Proper use requires the product, whether a powder or solution, to be dissolved in fresh potable water immediately prior to administration. The resulting medicated liquid must be consumed within a stability window of 12 to 24 hours, after which any unused portion must be discarded to maintain potency.

Specialized instructions govern the product’s use in certain populations, such as the restriction of administration to pre-ruminant calves, lambs, and kids. Furthermore, guidelines state that the product should not be mixed with other veterinary medicinal products in the same solution, as this may compromise the stability of the active ingredient.

---

Summary of Use Protocol

The protocol structures the use of Colifarm as a short-term, daily oral treatment where the procedural focus is on the accurate delivery of the prescribed mg/kg dose over the defined course duration. Adherence to preparation rules and consumption time limits ensures the standardized application of the medicine.

Research Evidence / Overview of Studies for Colifarm

The research base for Colifarm (flumequine) is established primarily within the field of veterinary medicine, where it was studied for bacterial challenges in food-producing animals. The available evidence structure focuses heavily on pharmacokinetic (PK)—which describes how the drug moves through the body—and residue depletion studies, which track the compound’s presence in edible tissues over time.

---

Research on Acute Bacterial Infections in Livestock

This section summarizes the structure of the regulatory research and controlled studies that examined the active compound's behavior in pigs, broiler chickens, and turkeys for conditions characterized by high bacterial load in the digestive tract. The studies examined short-term drug concentrations in plasma and target tissues, as well as clinical markers, including survival endpoints, that were observed in the studies during the study period.

Data for certain groups remain insufficient regarding whether the achieved drug concentrations were consistently adequate in all measured tissues throughout the entire study. Furthermore, studies report how symptoms evolved in the observed populations, but inherent variability in drug intake when the medicine is administered through drinking water was associated with uneven exposure among the animals studied.

Research on Bacterial Challenges in Farmed Fish

Controlled studies in fish populations examined survival endpoints, microbiological clearance rates, and environmental impact. Findings were mixed regarding patterns of growth; research conducted in highly controlled laboratory tanks sometimes reported different patterns compared to data from larger pond systems. Evidence quality varies across studies.

What is Still Uncertain About the Research Evidence

This final summary synthesizes the main evidence gaps and limitations noted in the scientific literature. Comparative evidence is lacking for the clinical outcomes of this compound against newer antibiotics in the same class in head-to-head trials. Certainty remains low on the clinical significance of the low PK/PD ratios that were observed in some studies in turkeys. Research provides context but not individual predictions for how an animal will respond or clear residues.

Key Studies & References Summary of Product Characteristics (SPC) for Colifarm (Flumequine) - Irish Health Products Regulatory Authority (HPRA)

Common questions about Colifarm (FAQ)

---

Q: How long does the effect of one dose of Colifarm typically last?

The active ingredient in Colifarm, Flumequine, is tracked by regulatory bodies in treated animals. Official documents report its elimination half-life is typically around 5 to 6 hours. The half-life refers to the time it takes for the concentration of the substance in the body to be reduced by half.

---

Q: What are the age restrictions for using Colifarm?

According to the official product information, this veterinary medicine is authorized for use only in specific production animals, such as calves, pigs, poultry, and farmed fish. Use is specifically restricted to pre-ruminant calves, lambs, and kids, and is prohibited in laying hens that produce eggs for human consumption.

---

Q: What kind of evidence supports the uses of Colifarm?

Regulatory evidence supporting the use of the active ingredient (Flumequine) is based on studies conducted in food-producing animals. This evidence includes pharmacokinetic (PK) data, which tracks how the drug moves through the animal’s body, and residue depletion studies, which track its presence in edible tissues over time.

---

Q: Is Colifarm a prescription-only drug?

In most international regulatory jurisdictions, the active ingredient Flumequine, in its authorized veterinary form, is classified as a Prescription Drug (Rx). This classification reflects its regulatory status, requiring authorization for distribution and use.

---

Q: Do people typically need to take Colifarm for a long time?

Official documents define the authorized use of Colifarm (Flumequine) in animals as a short, finite course. Treatment regimens typically last between 3 to 5 consecutive days to manage the specific bacterial challenges it is designed to address.

---

Q: I see different strengths of Colifarm available. Why is this?

The product is manufactured in different strengths (concentrations) to allow for the precise and accurate preparation of the prescribed dosage. The availability of various concentrations is intended to support the accurate delivery of the calculated dose.

---

Q: Does Colifarm require any special considerations regarding diet?

Regulatory information indicates that administration must be separated from products containing metal cations (such as certain mineral supplements or iron salts) by a specified time interval to prevent reduced absorption. In monogastric animals, some documents note that food intake can potentially decrease the drug’s overall efficiency.

---

Q: Is it normal to feel a mild stomach upset when starting Colifarm?

The active ingredient in Colifarm belongs to the quinolone class of antibiotics. In animal studies, adverse effects reported for this class include potential gastrointestinal upset such such as vomiting, diarrhea, and colitis. No specific human safety data has been published by major health regulatory bodies for this product.

---

Q: Why do some patient information leaflets say Colifarm can be used for more than one condition?

The active substance Flumequine is indicated in veterinary medicine for treating a variety of enteric infections caused by susceptible bacteria. This broad range of use covers multiple conditions characterized by high bacterial load, such as infections related to E. coli (colibacillosis) and Salmonella (salmonellosis).

---

Q: Why do some users report they didn't feel any effect from Colifarm?

Veterinary research documents have identified that the method of administration (through drinking water) can result in variable exposure to the active ingredient. This variability in exposure among treated animals may be associated with inconsistent results.

---

Q: What is the half-life of Colifarm, described in simple terms?

The half-life refers to the time it takes for the body to eliminate half of the administered dose. For the active ingredient Flumequine in treated animals, the half-life is consistently reported in official documents as approximately 5 to 6 hours.

---

Q: Is it true that Colifarm can affect liver function?

Regulatory documents addressing drug interactions indicate a specific constraint regarding use in individuals with pre-existing renal or hepatic (liver) impairment, particularly in combination with Colchicine. This indicates that regulatory documents have constraints related to pre-existing hepatic impairment.

---

Q: Are there specific food items that must be avoided while on Colifarm?

Regulatory information indicates that products containing metal cations, such as iron salts or some antacids, require a specific time separation from Colifarm to prevent reduced absorption. These metal cations can bind to the medicine and significantly reduce the amount absorbed.

---

Q: Is Colifarm a medicine that cures a condition or just manages symptoms?

The active substance Flumequine is classified as definitively bactericidal, meaning it is designed to actively kill susceptible bacteria. Its general purpose is the comprehensive eradication of bacterial disease, rather than simply the management of symptoms.

---

Q: Do studies suggest Colifarm is effective for a wide range of patients?

The official scope of the studies for this product is exclusively focused on its effectiveness in specific production animals (e.g., calves, pigs, poultry, fish) authorized for treatment.

---

Q: What are the legal conditions under which Colifarm can be sold?

The sale and use of the product are strictly tied to country-specific regulatory approval for veterinary use. Additionally, all treated animals must observe a mandatory, legally defined withdrawal period before their products (meat, eggs) can enter the human food chain.

How to Store and Dispose of Colifarm (Flumequine Oral Solution)

The storage and disposal of Colifarm must adhere to strict regulatory guidelines to maintain product integrity and environmental safety. The medicine must be stored at or below 25°C and not be frozen. Keep the solution in its original container and ensure the bottle is tightly closed.

---

Stability and Child Safety

The product's shelf life is 3 years when unopened, but this is reduced to 3 months after the first opening, provided correct storage is maintained. The medicine must always be kept out of the sight and reach of children.

---

Disposal Requirements

Discard any unused or expired product according to local requirements. The official labeling mandates that the product must not contaminate ponds, waterways or ditches.